Corporate ProfileG1 Therapeutics is a clinical-stage biopharmaceutical company focused on the discovery and development of novel therapeutics for the treatment of cancer. G1’s two clinical assets, trilaciclib and G1T38, are CDK4/6 inhibitors, a validated and promising class of targets for anti-cancer therapeutics. Trilaciclib and G1T38 have broad therapeutic potential in many forms of cancer and may serve as the backbone of multiple combination regimens. In addition, G1 is advancing G1T48, a potential first/best-in-class oral selective estrogen receptor degrader, or SERD, which is targeted for the treatment of ER+ breast cancer. G1 owns or holds an exclusive license for worldwide commercial rights to each of its product candidates.
Stock Information

GTHX (Common Stock)


 0.02 (0.10%)


11/24/17 1:00 p.m. ET

Stock chart for: GTHX.O.  Currently trading at $20.82 with a 52 week high of $28.67 and a 52 week low of $12.04.
Recent NewsMore >>
11/08/17G1 Therapeutics Reports Third Quarter 2017 Financial Results and Recent Operational HighlightsPrinter Friendly Version
11/08/17G1 Therapeutics Makes Key Executive AppointmentsPrinter Friendly Version
11/07/17G1 Therapeutics to Present at Stifel 2017 Healthcare ConferencePrinter Friendly Version
11/06/17G1 Therapeutics Announces Publication in Cancer Discovery Demonstrating That CDK4/6 Inhibition Enhances the Anti-Tumor T Cell ResponsePrinter Friendly Version
Upcoming EventsMore >>
There are currently no events scheduled.
Data provided by Nasdaq. Minimum 15 minutes delayed.